90347-66-3

Basic information

• Product Name: METHYL 3-IODO-4-METHYLBENZOATE
• Synonyms: 3-IODO-4-METHYLBENZOIC ACID METHYL ESTER;METHYL 3-IODO-4-METHYLBENZOATE;METHYL 3-IODO-4-METH;2-Iodo-4-(methoxycarbonyl)toluene, Methyl 3-iodo-p-toluate
• CAS NO: 90347-66-3
• Molecular Formula: C₉H₉IO₂
• Molecular Weight: 276.07
• Product Categories: Aromatic Esters;Miscellaneous;Acids & Esters;Iodine Compounds;Benzenes
• Mol File: 90347-66-3.mol
• Article Data: 20

Chemical Properties

• Melting Point: 93-95
• Boiling Point: 302.9 °C at 760 mmHg
• Flash Point: 137 °C
• Appearance: /
• Density: 1.666g/cm³
• Vapor Pressure: 0.000961mmHg at 25°C
• Refractive Index: 1.5975
• Storage Temp.: 2-8°C(protect from light)
• Water Solubility: Not miscible or difficult to mix with water.
• Sensitive: Light Sensitive
• CAS DataBase Reference: METHYL 3-IODO-4-METHYLBENZOATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 3-IODO-4-METHYLBENZOATE(90347-66-3)
• EPA Substance Registry System: METHYL 3-IODO-4-METHYLBENZOATE(90347-66-3)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 90347-66-3(Hazardous Substances Data)

Usage

Chemical Properties

White crystalline

Uses

Methyl 3-Iodo-4-methylbenzoate is used as a reagent in the synthesis of [(pyrazolo[1,5-a]pyridmidinyl)ethynyl]benzamides as selective discoidin domain receptor 1 (DDR1) inhibitors. Also used as a reagent in the preparation of orally bioavailable GZD824 targeting Breakpoint Cluster Region-Abelson (Bcr-Abl) kinase and overcoming antitumor drug resistance.

InChI:InChI=1/C9H9IO2/c1-6-3-4-7(5-8(6)10)9(11)12-2/h3-5H,1-2H3

Upstream product

• 67-56-1 methanol 
• 82998-57-0 3-iodo-4-toluic acid 
• 186581-53-3 diazomethane 
• 144-55-8 sodium hydrogencarbonate 
• 18595-18-1 3-amino-4-methyl benzoic acid methyl ester 

Downstream Products

• 917392-54-2 methyl 4-methyl-3 -[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]benzoate 
• 1383854-47-4 methyl 3-(2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-5-yl)-4-methylbenzoate 
• 1257628-64-0 4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-(2-(pyrazolo[1,5-a]pyrimidin-6-yl)ethynyl)benzamide 
• 956697-54-4 4'-cyano-6-methyl-biphenyl-3-carboxylic acid [4-(morpholine-4-sulfonyl)phenyl]amide 

Relevant articles and documents

Design, Synthesis, and in vitro Evaluation of P2X7 Antagonists

The P2X7 receptor is a promising target for the treatment of various diseases due to its significant role in inflammation and immune cell signaling. This work describes the design, synthesis, and in vitro evaluation of a series of novel derivatives bearing diverse scaffolds as potent P2X7 antagonists. Our approach was based on structural modifications of reported (adamantan-1-yl)methylbenzamides able to inhibit the receptor activation. The adamantane moieties and the amide bond were replaced, and the replacements were evaluated by a ligand-based pharmacophore model. The antagonistic potency of the synthesized analogues was assessed by two-electrode voltage clamp experiments, using Xenopus laevis oocytes that express the human P2X7 receptor. SAR studies suggested that the replacement of the adamantane ring by an aryl-cyclohexyl moiety afforded the most potent antagonists against the activation of the P2X7 cation channel, with analogue 2-chloro-N-[1-(3-(nitrooxymethyl)phenyl)cyclohexyl)methyl]benzamide (56) exhibiting the best potency with an IC50 value of 0.39 μΜ.

KINASE INHIBITORS AND USES THEREOF

This invention described herein relates to compounds of general formula (I) : (I), in which variable groups are as defined herein, and to their preparation and use. Uses for the compounds and for compositions containing them include treatment of cancer and other diseases mediated by protein kinases, such as Bcr-Abl kinase, and mutants thereof, such as the T315I mutant.

3-ACETYLENYL-PYRAZOLE-PYRIMIDINE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USES THEREOF

The present invention relates to the field of chemical and medicine, more particularly, 3-ethynylpyrazolopyrimidine derivatives and their preparation methods and uses. The invention provides a 3-ethynylpyrazolopyrimidine derivative, and the structure is shown in formula I. The present invention also provides preparation methods and use of 3-ethynylpyrazolopyrimidine derivatives, comprising the compounds and derivatives, and their pharmaceutical compositions for the use of the treatment and prevention of tumors.